** Shares of ophthalmic medical device company Rxsight RXST.O fall 23.8% to $19.9 premarket
** Co late on Wednesday lowered its annual revenue forecast to range between $160.0 million and $175.0 million from a previous range of $185 million to $197 million
** RXST expects preliminary Q1 revenue of $37.9 million, lower than analysts' average estimate of $39.59 million as per data compiled by LSEG
** 8 out of 10 brokerages rate the stock "buy" or higher, 2 rate "hold" and their median PT is $43 - LSEG data
** Up to last close, RXST stock has fallen 93% in the past 12 months
(Reporting by Padmanabhan Ananthan)
((Padmanabhan.Ananthan@thomsonreuters.com))
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。